| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cognitive Dysfunction | 60 | 2024 | 1095 | 10.000 |
Why?
|
| Alzheimer Disease | 86 | 2024 | 2137 | 8.300 |
Why?
|
| Cognition | 75 | 2023 | 1428 | 7.700 |
Why?
|
| Aging | 71 | 2023 | 1729 | 7.360 |
Why?
|
| Aged | 191 | 2024 | 10082 | 5.280 |
Why?
|
| Dementia | 26 | 2024 | 561 | 4.470 |
Why?
|
| Aged, 80 and over | 133 | 2024 | 5197 | 3.940 |
Why?
|
| Brain | 36 | 2023 | 1797 | 3.630 |
Why?
|
| Humans | 232 | 2024 | 31073 | 3.580 |
Why?
|
| Cognition Disorders | 34 | 2022 | 1057 | 3.450 |
Why?
|
| Independent Living | 16 | 2023 | 321 | 3.430 |
Why?
|
| Male | 171 | 2023 | 16499 | 3.170 |
Why?
|
| Female | 170 | 2023 | 17017 | 3.110 |
Why?
|
| Neuropsychological Tests | 51 | 2022 | 1317 | 2.730 |
Why?
|
| Depression | 14 | 2023 | 481 | 2.710 |
Why?
|
| Longitudinal Studies | 57 | 2023 | 1507 | 2.490 |
Why?
|
| Diet, Mediterranean | 8 | 2023 | 93 | 2.320 |
Why?
|
| Exercise | 12 | 2021 | 505 | 2.280 |
Why?
|
| Stress, Psychological | 7 | 2023 | 254 | 2.200 |
Why?
|
| Apolipoproteins E | 18 | 2023 | 270 | 2.130 |
Why?
|
| HIV Infections | 5 | 2021 | 888 | 2.070 |
Why?
|
| Risk Factors | 44 | 2023 | 2591 | 1.840 |
Why?
|
| Cohort Studies | 46 | 2023 | 2046 | 1.820 |
Why?
|
| Tissue Donors | 3 | 2020 | 81 | 1.740 |
Why?
|
| Educational Status | 14 | 2023 | 312 | 1.690 |
Why?
|
| Life Style | 8 | 2021 | 226 | 1.680 |
Why?
|
| Cognitive Aging | 7 | 2020 | 87 | 1.570 |
Why?
|
| Magnetic Resonance Imaging | 14 | 2023 | 1318 | 1.570 |
Why?
|
| Motor Activity | 7 | 2016 | 370 | 1.420 |
Why?
|
| Memory Disorders | 6 | 2020 | 178 | 1.420 |
Why?
|
| Chicago | 32 | 2021 | 941 | 1.370 |
Why?
|
| Memory | 12 | 2021 | 330 | 1.370 |
Why?
|
| Body Mass Index | 4 | 2021 | 453 | 1.330 |
Why?
|
| Middle Aged | 44 | 2023 | 10240 | 1.310 |
Why?
|
| Self Report | 6 | 2021 | 231 | 1.290 |
Why?
|
| Genetic Predisposition to Disease | 15 | 2021 | 465 | 1.280 |
Why?
|
| United States | 28 | 2024 | 2376 | 1.280 |
Why?
|
| Arteriolosclerosis | 4 | 2023 | 82 | 1.260 |
Why?
|
| Apolipoprotein E4 | 12 | 2023 | 258 | 1.220 |
Why?
|
| Sex Characteristics | 5 | 2023 | 144 | 1.210 |
Why?
|
| Hypertension | 5 | 2022 | 288 | 1.160 |
Why?
|
| Membrane Transport Proteins | 4 | 2021 | 60 | 1.140 |
Why?
|
| Geriatric Assessment | 13 | 2021 | 238 | 1.120 |
Why?
|
| White Matter | 5 | 2022 | 157 | 1.110 |
Why?
|
| Caregivers | 5 | 2017 | 156 | 1.100 |
Why?
|
| Genotype | 17 | 2023 | 428 | 1.090 |
Why?
|
| Disease Progression | 18 | 2021 | 833 | 1.050 |
Why?
|
| Cross-Sectional Studies | 14 | 2022 | 1006 | 1.050 |
Why?
|
| Neuroimaging | 4 | 2022 | 144 | 0.970 |
Why?
|
| Cerebral Cortex | 4 | 2021 | 196 | 0.960 |
Why?
|
| Positron-Emission Tomography | 3 | 2023 | 98 | 0.950 |
Why?
|
| Prejudice | 4 | 2009 | 41 | 0.950 |
Why?
|
| Adaptation, Psychological | 2 | 2022 | 147 | 0.930 |
Why?
|
| Haplotypes | 3 | 2021 | 64 | 0.920 |
Why?
|
| Cytomegalovirus Infections | 2 | 2015 | 83 | 0.900 |
Why?
|
| Mobility Limitation | 5 | 2020 | 102 | 0.900 |
Why?
|
| Parkinsonian Disorders | 6 | 2023 | 234 | 0.890 |
Why?
|
| Family | 3 | 2021 | 100 | 0.890 |
Why?
|
| Activities of Daily Living | 11 | 2022 | 551 | 0.880 |
Why?
|
| Disabled Persons | 3 | 2021 | 135 | 0.850 |
Why?
|
| Memory, Episodic | 7 | 2023 | 128 | 0.840 |
Why?
|
| Flavonols | 1 | 2022 | 12 | 0.840 |
Why?
|
| Empathy | 1 | 2022 | 40 | 0.830 |
Why?
|
| Healthy Aging | 4 | 2023 | 16 | 0.830 |
Why?
|
| Social Participation | 1 | 2022 | 12 | 0.820 |
Why?
|
| Patient Participation | 1 | 2022 | 53 | 0.810 |
Why?
|
| Minority Groups | 3 | 2020 | 74 | 0.790 |
Why?
|
| Cerebrovascular Disorders | 5 | 2023 | 149 | 0.780 |
Why?
|
| Surveys and Questionnaires | 14 | 2021 | 1209 | 0.770 |
Why?
|
| Socioeconomic Factors | 11 | 2019 | 334 | 0.770 |
Why?
|
| Dietary Approaches To Stop Hypertension | 2 | 2021 | 31 | 0.770 |
Why?
|
| Plaque, Amyloid | 5 | 2018 | 153 | 0.750 |
Why?
|
| Loneliness | 3 | 2017 | 61 | 0.730 |
Why?
|
| Factor Analysis, Statistical | 3 | 2015 | 79 | 0.730 |
Why?
|
| Social Segregation | 1 | 2020 | 8 | 0.720 |
Why?
|
| Sex Factors | 11 | 2021 | 510 | 0.710 |
Why?
|
| Disability Evaluation | 7 | 2016 | 333 | 0.690 |
Why?
|
| Health Equity | 1 | 2020 | 19 | 0.690 |
Why?
|
| Physical Fitness | 1 | 2020 | 60 | 0.690 |
Why?
|
| Amyloid beta-Peptides | 11 | 2023 | 328 | 0.680 |
Why?
|
| Neurofibrillary Tangles | 4 | 2019 | 199 | 0.670 |
Why?
|
| Cardiovascular Diseases | 5 | 2023 | 428 | 0.670 |
Why?
|
| Follow-Up Studies | 21 | 2019 | 1935 | 0.670 |
Why?
|
| Polymorphism, Single Nucleotide | 8 | 2021 | 318 | 0.660 |
Why?
|
| tau Proteins | 8 | 2023 | 229 | 0.660 |
Why?
|
| Social Environment | 5 | 2021 | 87 | 0.660 |
Why?
|
| Lewy Bodies | 5 | 2023 | 206 | 0.650 |
Why?
|
| TDP-43 Proteinopathies | 4 | 2021 | 113 | 0.650 |
Why?
|
| Age Factors | 13 | 2021 | 875 | 0.630 |
Why?
|
| Residence Characteristics | 7 | 2021 | 225 | 0.620 |
Why?
|
| Patient Selection | 3 | 2020 | 246 | 0.610 |
Why?
|
| Social Support | 6 | 2016 | 194 | 0.600 |
Why?
|
| Atherosclerosis | 3 | 2023 | 76 | 0.600 |
Why?
|
| Life Change Events | 2 | 2020 | 38 | 0.600 |
Why?
|
| Accelerometry | 5 | 2021 | 94 | 0.590 |
Why?
|
| Adult | 17 | 2023 | 8950 | 0.580 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2019 | 190 | 0.570 |
Why?
|
| Mental Status and Dementia Tests | 4 | 2021 | 89 | 0.570 |
Why?
|
| Attitude to Health | 1 | 2017 | 99 | 0.550 |
Why?
|
| Prospective Studies | 17 | 2022 | 1899 | 0.540 |
Why?
|
| Genome-Wide Association Study | 8 | 2021 | 320 | 0.540 |
Why?
|
| Blood Pressure | 4 | 2022 | 262 | 0.540 |
Why?
|
| Research Design | 5 | 2021 | 219 | 0.520 |
Why?
|
| Neuropathology | 4 | 2023 | 87 | 0.520 |
Why?
|
| Racism | 2 | 2023 | 35 | 0.520 |
Why?
|
| Odds Ratio | 8 | 2018 | 293 | 0.520 |
Why?
|
| Program Evaluation | 1 | 2016 | 136 | 0.510 |
Why?
|
| Motor Disorders | 1 | 2015 | 25 | 0.490 |
Why?
|
| Sleep Wake Disorders | 1 | 2016 | 149 | 0.490 |
Why?
|
| Social Behavior | 4 | 2011 | 103 | 0.490 |
Why?
|
| Wearable Electronic Devices | 3 | 2020 | 43 | 0.480 |
Why?
|
| Risk Reduction Behavior | 1 | 2015 | 56 | 0.480 |
Why?
|
| Lewy Body Disease | 4 | 2021 | 104 | 0.470 |
Why?
|
| Health Literacy | 3 | 2021 | 108 | 0.470 |
Why?
|
| gamma-Tocopherol | 1 | 2014 | 8 | 0.470 |
Why?
|
| alpha-Tocopherol | 1 | 2014 | 11 | 0.470 |
Why?
|
| Health Behavior | 3 | 2020 | 163 | 0.460 |
Why?
|
| Cognitive Reserve | 2 | 2011 | 41 | 0.460 |
Why?
|
| Genetic Loci | 4 | 2021 | 65 | 0.460 |
Why?
|
| Acculturation | 3 | 2023 | 40 | 0.450 |
Why?
|
| Reaction Time | 3 | 2021 | 128 | 0.450 |
Why?
|
| Psychometrics | 8 | 2012 | 270 | 0.440 |
Why?
|
| Quality of Life | 6 | 2020 | 696 | 0.420 |
Why?
|
| Income | 3 | 2022 | 79 | 0.410 |
Why?
|
| Alleles | 7 | 2023 | 236 | 0.410 |
Why?
|
| Interpersonal Relations | 5 | 2009 | 111 | 0.410 |
Why?
|
| Psychomotor Performance | 7 | 2020 | 218 | 0.390 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2016 | 214 | 0.390 |
Why?
|
| Psychiatric Status Rating Scales | 6 | 2015 | 356 | 0.390 |
Why?
|
| Behavioral Symptoms | 1 | 2011 | 14 | 0.380 |
Why?
|
| Databases, Factual | 2 | 2020 | 354 | 0.380 |
Why?
|
| Intracranial Arteriosclerosis | 2 | 2022 | 55 | 0.370 |
Why?
|
| Executive Function | 5 | 2023 | 125 | 0.370 |
Why?
|
| Cerebral Amyloid Angiopathy | 2 | 2023 | 120 | 0.370 |
Why?
|
| Parkinson Disease | 4 | 2023 | 1066 | 0.360 |
Why?
|
| Mortality | 3 | 2020 | 89 | 0.360 |
Why?
|
| Linear Models | 10 | 2020 | 273 | 0.360 |
Why?
|
| Biomarkers | 5 | 2022 | 734 | 0.350 |
Why?
|
| Mental Status Schedule | 7 | 2018 | 121 | 0.350 |
Why?
|
| Autopsy | 5 | 2023 | 352 | 0.350 |
Why?
|
| Life | 2 | 2006 | 9 | 0.340 |
Why?
|
| Decision Making | 4 | 2022 | 236 | 0.340 |
Why?
|
| Reading | 5 | 2021 | 46 | 0.330 |
Why?
|
| Incidence | 7 | 2021 | 790 | 0.330 |
Why?
|
| Hostility | 1 | 2009 | 22 | 0.330 |
Why?
|
| Receptors, Immunologic | 2 | 2021 | 36 | 0.330 |
Why?
|
| C-Reactive Protein | 1 | 2009 | 128 | 0.330 |
Why?
|
| Cities | 2 | 2021 | 15 | 0.320 |
Why?
|
| Psychology | 3 | 2021 | 24 | 0.320 |
Why?
|
| DNA-Binding Proteins | 3 | 2022 | 274 | 0.320 |
Why?
|
| Membrane Glycoproteins | 2 | 2021 | 107 | 0.320 |
Why?
|
| Olfaction Disorders | 2 | 2021 | 57 | 0.310 |
Why?
|
| Antihypertensive Agents | 2 | 2019 | 88 | 0.300 |
Why?
|
| Data Collection | 3 | 2021 | 109 | 0.290 |
Why?
|
| Models, Psychological | 3 | 2015 | 70 | 0.290 |
Why?
|
| Personal Space | 1 | 2007 | 7 | 0.280 |
Why?
|
| Apolipoprotein E2 | 2 | 2023 | 14 | 0.270 |
Why?
|
| Gray Matter | 3 | 2020 | 59 | 0.270 |
Why?
|
| Homozygote | 2 | 2017 | 25 | 0.270 |
Why?
|
| Cerebral Infarction | 4 | 2020 | 164 | 0.270 |
Why?
|
| Medicare | 2 | 2024 | 127 | 0.260 |
Why?
|
| Case-Control Studies | 6 | 2019 | 664 | 0.260 |
Why?
|
| Population Surveillance | 3 | 2019 | 123 | 0.250 |
Why?
|
| Vitamin D | 2 | 2022 | 42 | 0.250 |
Why?
|
| Nervous System Diseases | 2 | 2020 | 156 | 0.250 |
Why?
|
| Inflammation | 2 | 2022 | 361 | 0.250 |
Why?
|
| Memory, Short-Term | 2 | 2022 | 104 | 0.250 |
Why?
|
| Clinical Trials as Topic | 2 | 2020 | 331 | 0.240 |
Why?
|
| Proportional Hazards Models | 6 | 2020 | 370 | 0.240 |
Why?
|
| Healthy Lifestyle | 2 | 2021 | 38 | 0.240 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2023 | 11 | 0.220 |
Why?
|
| Caloric Restriction | 1 | 2023 | 16 | 0.220 |
Why?
|
| Time Factors | 7 | 2017 | 1680 | 0.220 |
Why?
|
| Tauopathies | 1 | 2023 | 20 | 0.220 |
Why?
|
| Health Status Disparities | 2 | 2014 | 73 | 0.220 |
Why?
|
| Hippocampus | 2 | 2022 | 284 | 0.220 |
Why?
|
| Urban Population | 4 | 2013 | 148 | 0.220 |
Why?
|
| Reproducibility of Results | 4 | 2021 | 820 | 0.210 |
Why?
|
| Kaempferols | 1 | 2022 | 13 | 0.210 |
Why?
|
| Quercetin | 1 | 2022 | 16 | 0.210 |
Why?
|
| Prevalence | 4 | 2021 | 499 | 0.210 |
Why?
|
| Diabetes Complications | 3 | 2020 | 68 | 0.210 |
Why?
|
| Healthy Volunteers | 2 | 2020 | 49 | 0.210 |
Why?
|
| Postural Balance | 2 | 2018 | 124 | 0.210 |
Why?
|
| Perception | 2 | 2021 | 85 | 0.210 |
Why?
|
| Qualitative Research | 1 | 2023 | 117 | 0.210 |
Why?
|
| Eating | 1 | 2022 | 55 | 0.210 |
Why?
|
| Radar | 1 | 2022 | 7 | 0.200 |
Why?
|
| Illinois | 3 | 2020 | 267 | 0.200 |
Why?
|
| Motivation | 1 | 2023 | 103 | 0.200 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2023 | 86 | 0.200 |
Why?
|
| Vegetables | 2 | 2021 | 20 | 0.200 |
Why?
|
| Desegregation | 1 | 2021 | 2 | 0.200 |
Why?
|
| Housing | 1 | 2021 | 16 | 0.200 |
Why?
|
| Apolipoprotein E3 | 2 | 2023 | 18 | 0.200 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2022 | 29 | 0.200 |
Why?
|
| Lutein | 1 | 2021 | 5 | 0.200 |
Why?
|
| Zeaxanthins | 1 | 2021 | 5 | 0.200 |
Why?
|
| Carotenoids | 1 | 2021 | 13 | 0.200 |
Why?
|
| Elder Abuse | 1 | 2022 | 35 | 0.190 |
Why?
|
| Blood Glucose | 1 | 2022 | 120 | 0.190 |
Why?
|
| Gender Identity | 2 | 2018 | 24 | 0.190 |
Why?
|
| Peptide Fragments | 2 | 2018 | 98 | 0.190 |
Why?
|
| Poly T | 1 | 2021 | 3 | 0.190 |
Why?
|
| Probability | 1 | 2021 | 99 | 0.190 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 66 | 0.190 |
Why?
|
| Brazil | 4 | 2021 | 46 | 0.190 |
Why?
|
| Amygdala | 1 | 2021 | 50 | 0.190 |
Why?
|
| Social Discrimination | 1 | 2021 | 8 | 0.190 |
Why?
|
| Receptors, IgG | 1 | 2021 | 21 | 0.190 |
Why?
|
| Amnesia | 1 | 2021 | 29 | 0.190 |
Why?
|
| Overweight | 1 | 2021 | 69 | 0.190 |
Why?
|
| Diet, Western | 1 | 2021 | 12 | 0.190 |
Why?
|
| Anomie | 2 | 2012 | 6 | 0.180 |
Why?
|
| Attitude to Death | 1 | 2020 | 16 | 0.180 |
Why?
|
| Health Status | 4 | 2011 | 239 | 0.180 |
Why?
|
| Neurofilament Proteins | 1 | 2020 | 7 | 0.180 |
Why?
|
| Risk | 4 | 2016 | 223 | 0.180 |
Why?
|
| Literacy | 1 | 2021 | 17 | 0.180 |
Why?
|
| Southeastern United States | 1 | 2020 | 10 | 0.180 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2020 | 31 | 0.180 |
Why?
|
| Music | 1 | 2021 | 21 | 0.180 |
Why?
|
| Tissue and Organ Procurement | 1 | 2020 | 35 | 0.180 |
Why?
|
| Causality | 1 | 2020 | 54 | 0.180 |
Why?
|
| Death | 1 | 2021 | 53 | 0.180 |
Why?
|
| Lung | 1 | 2021 | 173 | 0.180 |
Why?
|
| Midwestern United States | 1 | 2020 | 70 | 0.180 |
Why?
|
| Social Isolation | 3 | 2018 | 27 | 0.180 |
Why?
|
| Confidence Intervals | 3 | 2017 | 97 | 0.180 |
Why?
|
| Brain Diseases | 1 | 2021 | 82 | 0.180 |
Why?
|
| ATP-Binding Cassette Transporters | 3 | 2016 | 21 | 0.180 |
Why?
|
| Brain Mapping | 1 | 2021 | 190 | 0.180 |
Why?
|
| Substantia Nigra | 1 | 2021 | 145 | 0.180 |
Why?
|
| Financing, Personal | 1 | 2020 | 20 | 0.180 |
Why?
|
| Focus Groups | 1 | 2020 | 86 | 0.170 |
Why?
|
| Gait | 3 | 2020 | 407 | 0.170 |
Why?
|
| Walking Speed | 1 | 2020 | 43 | 0.170 |
Why?
|
| Information Literacy | 1 | 2019 | 10 | 0.170 |
Why?
|
| Goals | 2 | 2010 | 45 | 0.170 |
Why?
|
| Economics | 1 | 2019 | 18 | 0.170 |
Why?
|
| Health Priorities | 1 | 2019 | 5 | 0.170 |
Why?
|
| Diagnosis | 2 | 2017 | 26 | 0.160 |
Why?
|
| Religion | 1 | 2019 | 41 | 0.160 |
Why?
|
| Immunity | 1 | 2019 | 26 | 0.160 |
Why?
|
| Genetic Variation | 2 | 2017 | 113 | 0.160 |
Why?
|
| Lipids | 1 | 2019 | 38 | 0.160 |
Why?
|
| Comorbidity | 3 | 2020 | 508 | 0.160 |
Why?
|
| Claudins | 1 | 2018 | 6 | 0.160 |
Why?
|
| Serpins | 1 | 2018 | 5 | 0.160 |
Why?
|
| Seasons | 1 | 2018 | 32 | 0.160 |
Why?
|
| Cause of Death | 2 | 2009 | 70 | 0.160 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 159 | 0.160 |
Why?
|
| Muscle Proteins | 1 | 2018 | 32 | 0.160 |
Why?
|
| Phytochemicals | 1 | 2017 | 4 | 0.150 |
Why?
|
| Plant Leaves | 1 | 2017 | 4 | 0.150 |
Why?
|
| Models, Statistical | 3 | 2021 | 135 | 0.150 |
Why?
|
| Antidepressive Agents | 1 | 2018 | 100 | 0.150 |
Why?
|
| Phospholipase C gamma | 1 | 2017 | 10 | 0.150 |
Why?
|
| Stroke | 1 | 2021 | 315 | 0.150 |
Why?
|
| Transcription Factors | 1 | 2018 | 172 | 0.140 |
Why?
|
| Polymorphism, Genetic | 1 | 2017 | 75 | 0.140 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2017 | 80 | 0.140 |
Why?
|
| Organic Anion Transporters, Sodium-Dependent | 1 | 2016 | 4 | 0.140 |
Why?
|
| Symporters | 1 | 2016 | 5 | 0.140 |
Why?
|
| Microfilament Proteins | 1 | 2016 | 23 | 0.140 |
Why?
|
| Immunity, Innate | 1 | 2017 | 97 | 0.140 |
Why?
|
| Social Class | 2 | 2021 | 69 | 0.140 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2018 | 144 | 0.140 |
Why?
|
| Data Interpretation, Statistical | 3 | 2022 | 100 | 0.140 |
Why?
|
| Logistic Models | 5 | 2018 | 411 | 0.140 |
Why?
|
| Agnosia | 1 | 2016 | 11 | 0.140 |
Why?
|
| Risk Assessment | 2 | 2022 | 718 | 0.140 |
Why?
|
| Seafood | 1 | 2016 | 10 | 0.140 |
Why?
|
| Task Performance and Analysis | 1 | 2016 | 53 | 0.140 |
Why?
|
| Microglia | 1 | 2017 | 132 | 0.140 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2016 | 18 | 0.140 |
Why?
|
| Statistics, Nonparametric | 2 | 2015 | 143 | 0.130 |
Why?
|
| Chronic Disease | 2 | 2009 | 534 | 0.130 |
Why?
|
| Hearing | 1 | 2015 | 23 | 0.130 |
Why?
|
| Feeding Behavior | 1 | 2016 | 101 | 0.130 |
Why?
|
| Diabetes Mellitus | 1 | 2017 | 148 | 0.130 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 555 | 0.120 |
Why?
|
| Home Nursing | 1 | 2015 | 20 | 0.120 |
Why?
|
| Neurodegenerative Diseases | 2 | 2021 | 119 | 0.120 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2015 | 22 | 0.120 |
Why?
|
| Diet | 3 | 2022 | 194 | 0.120 |
Why?
|
| Anxiety Disorders | 1 | 2016 | 171 | 0.120 |
Why?
|
| Motor Skills | 1 | 2015 | 61 | 0.120 |
Why?
|
| Demography | 4 | 2016 | 81 | 0.120 |
Why?
|
| Sensitivity and Specificity | 2 | 2021 | 586 | 0.120 |
Why?
|
| Adolescent | 3 | 2021 | 2403 | 0.110 |
Why?
|
| Young Adult | 3 | 2021 | 2061 | 0.110 |
Why?
|
| Locomotion | 1 | 2014 | 25 | 0.110 |
Why?
|
| Mental Health | 2 | 2016 | 113 | 0.110 |
Why?
|
| Forecasting | 1 | 2014 | 115 | 0.110 |
Why?
|
| Hormone Replacement Therapy | 1 | 2013 | 32 | 0.110 |
Why?
|
| Sleep | 1 | 2016 | 322 | 0.110 |
Why?
|
| Interviews as Topic | 3 | 2021 | 132 | 0.110 |
Why?
|
| Longevity | 1 | 2013 | 33 | 0.110 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2013 | 28 | 0.110 |
Why?
|
| Intention | 2 | 2010 | 28 | 0.110 |
Why?
|
| Child | 3 | 2013 | 1431 | 0.110 |
Why?
|
| Infarction | 2 | 2023 | 32 | 0.110 |
Why?
|
| Walking | 2 | 2020 | 258 | 0.110 |
Why?
|
| Menopause | 1 | 2013 | 131 | 0.100 |
Why?
|
| Awareness | 3 | 2018 | 41 | 0.100 |
Why?
|
| Epidemiologic Studies | 1 | 2012 | 24 | 0.100 |
Why?
|
| Automobile Driving | 1 | 2012 | 12 | 0.100 |
Why?
|
| Personality Inventory | 2 | 2009 | 75 | 0.100 |
Why?
|
| Association | 1 | 2011 | 9 | 0.100 |
Why?
|
| Dietary Supplements | 2 | 2022 | 63 | 0.100 |
Why?
|
| Niacinamide | 1 | 2011 | 6 | 0.100 |
Why?
|
| Cerebral Ventricles | 1 | 2011 | 23 | 0.090 |
Why?
|
| Vitamin E | 1 | 2011 | 29 | 0.090 |
Why?
|
| Environmental Health | 1 | 2010 | 10 | 0.090 |
Why?
|
| Hospitalization | 1 | 2013 | 336 | 0.090 |
Why?
|
| Neocortex | 1 | 2010 | 34 | 0.090 |
Why?
|
| Phobic Disorders | 1 | 2010 | 66 | 0.090 |
Why?
|
| Piperazines | 1 | 2011 | 91 | 0.090 |
Why?
|
| Medicare Part D | 1 | 2009 | 8 | 0.080 |
Why?
|
| Age of Onset | 3 | 2014 | 110 | 0.080 |
Why?
|
| Social Identification | 1 | 2009 | 7 | 0.080 |
Why?
|
| Severity of Illness Index | 3 | 2021 | 1134 | 0.080 |
Why?
|
| Diet Surveys | 2 | 2021 | 23 | 0.080 |
Why?
|
| Neuroticism | 2 | 2021 | 37 | 0.080 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2023 | 225 | 0.070 |
Why?
|
| Multivariate Analysis | 2 | 2009 | 344 | 0.070 |
Why?
|
| Muscle Strength Dynamometer | 1 | 2007 | 18 | 0.070 |
Why?
|
| Visual Acuity | 1 | 2007 | 52 | 0.070 |
Why?
|
| Heterozygote | 2 | 2018 | 108 | 0.070 |
Why?
|
| Neurologic Examination | 2 | 2020 | 138 | 0.070 |
Why?
|
| Genotyping Techniques | 2 | 2017 | 12 | 0.070 |
Why?
|
| Personality Disorders | 1 | 2006 | 20 | 0.070 |
Why?
|
| Child, Preschool | 2 | 2022 | 691 | 0.070 |
Why?
|
| Genetic Association Studies | 2 | 2017 | 91 | 0.070 |
Why?
|
| Smoking | 2 | 2017 | 197 | 0.070 |
Why?
|
| Child Abuse | 1 | 2006 | 38 | 0.070 |
Why?
|
| Cross-Cultural Comparison | 1 | 2005 | 41 | 0.060 |
Why?
|
| Linkage Disequilibrium | 2 | 2017 | 46 | 0.060 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2006 | 199 | 0.060 |
Why?
|
| Anisotropy | 1 | 2023 | 62 | 0.050 |
Why?
|
| Diet, Vegetarian | 1 | 2022 | 7 | 0.050 |
Why?
|
| Copper | 1 | 2022 | 16 | 0.050 |
Why?
|
| Vitamins | 1 | 2022 | 20 | 0.050 |
Why?
|
| Prognosis | 2 | 2019 | 924 | 0.050 |
Why?
|
| Unconsciousness | 1 | 2022 | 11 | 0.050 |
Why?
|
| Self Stimulation | 1 | 2002 | 12 | 0.050 |
Why?
|
| Sclerosis | 1 | 2022 | 71 | 0.050 |
Why?
|
| California | 1 | 2021 | 31 | 0.050 |
Why?
|
| Cerebral Hemorrhage | 1 | 2023 | 140 | 0.050 |
Why?
|
| Schools | 1 | 2021 | 51 | 0.050 |
Why?
|
| Spatial Processing | 1 | 2021 | 8 | 0.050 |
Why?
|
| Principal Component Analysis | 1 | 2021 | 28 | 0.050 |
Why?
|
| Fraud | 1 | 2021 | 24 | 0.050 |
Why?
|
| Mathematics | 1 | 2021 | 33 | 0.050 |
Why?
|
| Cost of Illness | 1 | 2021 | 56 | 0.050 |
Why?
|
| Writing | 1 | 2021 | 22 | 0.050 |
Why?
|
| Amyloid | 1 | 2021 | 58 | 0.050 |
Why?
|
| Late Onset Disorders | 1 | 2020 | 7 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2020 | 81 | 0.050 |
Why?
|
| Self-Assessment | 1 | 2020 | 32 | 0.050 |
Why?
|
| Early Diagnosis | 1 | 2020 | 69 | 0.040 |
Why?
|
| Wisconsin | 1 | 2020 | 6 | 0.040 |
Why?
|
| Fitness Trackers | 1 | 2019 | 15 | 0.040 |
Why?
|
| Movement | 1 | 2020 | 137 | 0.040 |
Why?
|
| Trust | 1 | 2019 | 17 | 0.040 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 33 | 0.040 |
Why?
|
| Renin-Angiotensin System | 1 | 2019 | 8 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 360 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2019 | 65 | 0.040 |
Why?
|
| Diagnostic Techniques, Neurological | 1 | 2018 | 12 | 0.040 |
Why?
|
| Time and Motion Studies | 1 | 2018 | 18 | 0.040 |
Why?
|
| Survival Rate | 2 | 2010 | 407 | 0.040 |
Why?
|
| Registries | 1 | 2020 | 203 | 0.040 |
Why?
|
| Neurotic Disorders | 1 | 2018 | 20 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2018 | 30 | 0.040 |
Why?
|
| Amyloidosis | 1 | 2018 | 28 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2020 | 3810 | 0.040 |
Why?
|
| Community Health Planning | 1 | 2018 | 23 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2021 | 3665 | 0.040 |
Why?
|
| Religious Personnel | 1 | 2018 | 12 | 0.040 |
Why?
|
| Exome | 1 | 2017 | 9 | 0.040 |
Why?
|
| Protein Interaction Maps | 1 | 2017 | 18 | 0.040 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2017 | 46 | 0.040 |
Why?
|
| Gene Expression | 1 | 2018 | 239 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2017 | 73 | 0.040 |
Why?
|
| Age Distribution | 2 | 2009 | 96 | 0.040 |
Why?
|
| Genetic Linkage | 1 | 2017 | 67 | 0.040 |
Why?
|
| Amino Acid Sequence | 1 | 2017 | 195 | 0.040 |
Why?
|
| Prefrontal Cortex | 1 | 2018 | 151 | 0.040 |
Why?
|
| Monitoring, Ambulatory | 1 | 2016 | 20 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 165 | 0.030 |
Why?
|
| Neuroprotection | 1 | 2016 | 4 | 0.030 |
Why?
|
| Mutation | 1 | 2018 | 409 | 0.030 |
Why?
|
| Gene-Environment Interaction | 1 | 2016 | 20 | 0.030 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 60 | 0.030 |
Why?
|
| Genes, Recessive | 1 | 2015 | 9 | 0.030 |
Why?
|
| Indiana | 1 | 2015 | 18 | 0.030 |
Why?
|
| Audiometry, Pure-Tone | 1 | 2015 | 11 | 0.030 |
Why?
|
| Auditory Threshold | 1 | 2015 | 16 | 0.030 |
Why?
|
| Brief Psychiatric Rating Scale | 1 | 2015 | 9 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2015 | 16 | 0.030 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 1 | 2015 | 17 | 0.030 |
Why?
|
| Psychological Tests | 1 | 2015 | 50 | 0.030 |
Why?
|
| Acoustic Stimulation | 1 | 2015 | 51 | 0.030 |
Why?
|
| Sex Distribution | 2 | 2005 | 90 | 0.030 |
Why?
|
| Sweden | 1 | 2015 | 10 | 0.030 |
Why?
|
| Psychomotor Agitation | 1 | 2015 | 14 | 0.030 |
Why?
|
| Protective Factors | 1 | 2015 | 20 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2015 | 116 | 0.030 |
Why?
|
| Pedigree | 1 | 2015 | 75 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 149 | 0.030 |
Why?
|
| Actigraphy | 1 | 2015 | 99 | 0.030 |
Why?
|
| Hypokinesia | 1 | 2014 | 28 | 0.030 |
Why?
|
| Muscle Rigidity | 1 | 2014 | 26 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2013 | 120 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2013 | 45 | 0.030 |
Why?
|
| Health Surveys | 1 | 2013 | 99 | 0.030 |
Why?
|
| Accidents, Traffic | 1 | 2012 | 14 | 0.030 |
Why?
|
| Licensure | 1 | 2012 | 10 | 0.030 |
Why?
|
| Spatial Behavior | 1 | 2012 | 13 | 0.030 |
Why?
|
| Tremor | 1 | 2014 | 141 | 0.030 |
Why?
|
| Multilevel Analysis | 1 | 2012 | 9 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2012 | 38 | 0.030 |
Why?
|
| Environment | 1 | 2012 | 47 | 0.020 |
Why?
|
| Retirement | 1 | 2011 | 12 | 0.020 |
Why?
|
| Bias | 1 | 2011 | 36 | 0.020 |
Why?
|
| Microcirculation | 1 | 2011 | 42 | 0.020 |
Why?
|
| Phenanthrolines | 1 | 2010 | 5 | 0.020 |
Why?
|
| Carbon Radioisotopes | 1 | 2010 | 8 | 0.020 |
Why?
|
| Peptidylprolyl Isomerase | 1 | 2010 | 7 | 0.020 |
Why?
|
| Thiazoles | 1 | 2010 | 31 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2010 | 65 | 0.020 |
Why?
|
| Aniline Compounds | 1 | 2010 | 46 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 301 | 0.020 |
Why?
|
| Housing for the Elderly | 1 | 2010 | 8 | 0.020 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2009 | 2 | 0.020 |
Why?
|
| Life Expectancy | 1 | 2009 | 22 | 0.020 |
Why?
|
| Baltimore | 1 | 2009 | 15 | 0.020 |
Why?
|
| Animals | 1 | 2018 | 4720 | 0.020 |
Why?
|
| Environment Design | 1 | 2009 | 10 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 409 | 0.020 |
Why?
|
| Safety | 1 | 2009 | 50 | 0.020 |
Why?
|
| Social Adjustment | 1 | 2006 | 31 | 0.020 |
Why?
|
| Parent-Child Relations | 1 | 2006 | 35 | 0.020 |
Why?
|
| Community Mental Health Centers | 1 | 2005 | 5 | 0.020 |
Why?
|
| Parenting | 1 | 2006 | 73 | 0.020 |
Why?
|
| Parents | 1 | 2006 | 110 | 0.020 |
Why?
|